Combo Treatment Assessed in Black Patients Co-Infected With HIV, HCV

Ledipasvir/sofosbuvir produced a high SVR12 in co-infected HCV/HIV patients
Ledipasvir/sofosbuvir produced a high SVR12 in co-infected HCV/HIV patients

This article is written live from ID Week 2017 Annual Meeting in San Diego, CA. MPR will be reporting news on the latest findings from leading experts in infectious diseases. Check back for more news from IDWeek 2017.

SAN DIEGO—For black patients co-infected with Hepatitis C Virus (HCV) and human immunodeficiency virus (HIV), treatment with ledipasvir/sofosbuvir (LDV/SOF) produced a high sustained virologic response-12 (SVR12) rate, according to real-world data presented at IDWeek 2017,

The study authors explained, “Retrospective chart reviews were conducted for Black, genotype 1 (GT1), HIV/HCV co-infected patients treated with LDV/SOF at 3 hospitals in Newark, NJ between January 2014 and July 2016.” Data regarding patient demographics, history of HCV treatment, and therapy duration and response was collected.

Of the total 107 patients included in the study, 65% were male, 26% had cirrhosis, and 77% had GT1a. The study authors noted that 31% of patients were treatment experienced, however, zero patients had prior NS5a treatment. “At baseline, median CD4 count was 680 cells/mm3, HIV viral load (VL) was <40 in 94% and median HCV VL was 2257403 IU/ml,” the study authors reported. Of the total patients, 29% switched antiretroviral treatment (ART) prior to therapy with LDV/SOF due to drug interactions. 

“Six, 89, and 12 patients completed 8, 12, and 24 weeks of LDV/SOF respectively,” the study authors reported. Overall, treatment with LDV/SOF yielded an SVR12 rate of 93%. The study authors also reported that SVR12 rates at 8 weeks, 12 weeks, and 24 weeks were 67%, 96%, and 92%, respectively. Overall, relapse occurred in 7 of 107 patients. Relapse rates at 8 weeks, 12 weeks, and 24 weeks were reported as 2/6, 4/89, and 1/12, respectively.

The study authors also reported SVR12 rates for INSTI-based therapy, PI-based therapy, therapy that included efavirenz, and other ART were 95%, 93%, 80%, and 91%, respectively. Additionally, relapse occurred in 3/65 patients using INSTI-based therapy, 1/14 patients using PI-based therapy, 1/5 patients using therapy including efavirenz, and 2/23 patients using other ART therapy.

For black patients co-infected with HIV and HCV, treatment with LDV/SOF yielded a high SVR12 rate. The authors noted that because only a small population of patients were included in the 8-week arm, efficacy of therapy is difficult to assess for this duration of therapy. The study authors concluded, “This data supports the overall high efficacy of LDV/SOF in a difficult-to-treat patient population.”

For continuous infectious disease news coverage from the IDWeek 2017, check back to MPR's IDWeek page for the latest updates.

Reference:

Banga J, Nizami S, Slim J, Nagarakanti S, Portilla M, Swaminathan S. Hepatitis C Virus Treatment Response to Ledipasvir/Sofosbuvir among patients co-infected with HIV and HCV: Real World Data in a Black Population. Poster presented at IDWeek; October 4–8, 2017; San Diego, CA. http://www.idweek.org.